Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.01 | N/A | +76.96% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.01 | N/A | +76.96% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the quarter's performance, particularly in terms of EPS. They highlighted ongoing advancements in their pipeline and upcoming milestones.
We are pleased with our progress this quarter.
Our pipeline continues to advance, and we are focused on our upcoming milestones.
Ionis Pharmaceuticals reported a smaller-than-expected loss per share, which led to a positive stock reaction, rising 6.64%. The company did not provide revenue figures or future guidance, but management's comments about progress in their pipeline suggest they are on track with their development goals. Investors may view the EPS beat as a sign of improving financial health.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
Archer-Daniels-Midland Company